Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.10.0.1
Commitments and Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 12, 2018
USD ($)
Jul. 27, 2017
EUR (€)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Operating Leased Assets [Line Items]                
Loss Contingency, Accrual, Current     $ 500,000     $ 500,000   $ 2,400,000
Loss Contingency Accrual, Provision     (100,000) $ 2,300,000   600,000 $ 3,300,000  
Legal Fees     $ 400,000 $ 400,000   $ 700,000 $ 1,200,000  
Loss Contingency, Damages Sought, Value $ 3,300,000              
Business Combination, Contingent Consideration Arrangements, Description         Fortress contended that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contended that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys’ fees, and Fortress filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma.      
Administration Fee Payable $ 37,000              
Dr. Falk Pharma [Member]                
Operating Leased Assets [Line Items]                
Proceeds from Legal Settlements | €   € 2.5            
Loss Contingency, Damages Paid, Value         $ 2,000,000      
Litigation Settlement, Expense         $ 39,500